Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Vir Biotechnology (VIR) to $20 from $15 and keeps a Buy rating on the shares. The firm says the “landmark” Astellas collaboration and “compelling” VIR-5500 Phase 1 data reshape Vir’s investment profile as a differentiated oncology company. In addition, Vir’s hepatitis D program is progressing ahead of schedule, the analyst tells investors in a research note. H.C. Wainwright believes Vir is well capitalized to execute across its dual franchises.